Hyonate (sodium hyaluronate), the anti-inflammatory treatment for lameness in horses previously owned by Bayer Healthcare, has been purchased by Merial Animal Health.

Previously offered by Bayer Healthcare, Hyonate is an established treatment of lameness in horses due to non-infectious inflammation of joints, using both intra-articular (IA) and intravenous (IV) injection.

As a major cause of decreased performance in horses, joint dysfunction can develop from repeated episodes of trauma that horses can experience in everyday work or competition, according to Louise Radford, Merial’s equine marketing and technical manager.

She said: “The beneficial effects of HA supplementation are attributable to the anti-inflammatory effects, improvement in viscoelastic properties of the synovial fluid, and interaction with the synovial membrane affecting pain transmission and joint metabolism.”

Positioned alongside Equioxx – the first COX-2 specific NSAID for horses – Hyonate provides equine vets with a choice of Merial-branded treatments for inflammation and joint disease.

Hyonate joins Merial’s portfolio of equine products including the UK’s first anti-ulcer prescription medicine GastroGard (omeprazole), ProteqFlu vaccines – the first and only in Europe to contain the most recent Florida Clade 1 and clade 2 strains – and “tried and trusted” wormers, Eqvalan (ivermectin) and Eqvalan Duo (ivermectin+ praziquantel).

  • For more information, call customer support on 0870 6000123 or contact your local Merial equine specialist.
View your activity >

Leave a Reply

Be the First to Comment!

Notify of